Literature DB >> 26738003

Gait rehabilitation with a high tech platform based on virtual reality conveys improvements in walking ability of children suffering from acquired brain injury.

E Biffi, E Beretta, E Diella, D Panzeri, C Maghini, A C Turconi, S Strazzer, G Reni.   

Abstract

The Gait Real-time Analysis Interactive Lab (GRAIL) is an instrumented multi-sensor platform based on immersive virtual reality for gait training and rehabilitation. Few studies have been included GRAIL to evaluate gait patterns in normal and disabled people and to improve gait in adults, while at our knowledge no evidence on its use for the rehabilitation of children is available. In this study, 4 children suffering from acquired brain injury (ABI) underwent a 5 session treatment with GRAIL, to improve walking and balance ability in engaging VR environments. The first and the last sessions were partially dedicated to gait evaluation. Results are promising: improvements were recorded at the ankle level, selectively at the affected side, and at the pelvic level, while small changes were measured at the hip and knee joints, which were already comparable to healthy subjects. All these changes also conveyed advances in the symmetry of the walking pattern. In the next future, a longer intervention will be proposed and more children will be enrolled to strongly prove the effectiveness of GRAIL in the rehabilitation of children with ABI.

Entities:  

Mesh:

Year:  2015        PMID: 26738003     DOI: 10.1109/EMBC.2015.7320103

Source DB:  PubMed          Journal:  Conf Proc IEEE Eng Med Biol Soc        ISSN: 1557-170X


  2 in total

1.  Motor Improvement in Adolescents Affected by Ataxia Secondary to Acquired Brain Injury: A Pilot Study.

Authors:  Elisabetta Peri; Daniele Panzeri; Elena Beretta; Gianluigi Reni; Sandra Strazzer; Emilia Biffi
Journal:  Biomed Res Int       Date:  2019-11-26       Impact factor: 3.411

Review 2.  Physical rehabilitation interventions in children with acquired brain injury: a scoping review.

Authors:  Christiaan Gmelig Meyling; Olaf Verschuren; Ingrid R Rentinck; Raoul H H Engelbert; Jan Willem Gorter
Journal:  Dev Med Child Neurol       Date:  2021-07-26       Impact factor: 4.864

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.